Maxlife: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://maxlife.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify “Maxlife” on the pictured label, suggesting Maxlife is the compounder of those drugs when in fact it is not.”

2. 2

   “Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website: “generic compounded medication” “With the same active ingredient as Wegovy® and Ozempic®, this treatment has been clinically tested and FDA-approved for effective weight management.” “With the same active ingredient as Mounjaro® and Zepbound®, this treatment has been clinically tested and FDA-approved for effective weight management.” “FDA Approved” “Active ingredients in Ozempic® & Wegovy®” “Active ingredients in Mounjaro® & Zepbound®””

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

maxlife.com returned a live site on 2026-08-09 titled "GLP-1 Weight Loss Program Online | MaxLife", advertising semaglutide and tirzepatide programmes "Starting at $155/mo" with a get-started flow and free expedited shipping.

Most letters in this roster are an argument about inference: a page says two products share an active ingredient, FDA says a reader will take that to mean the compounded one has been approved, and the copy is misleading for that reason. This one skips the argument. The page said "clinically tested and FDA-approved for effective weight management" and carried an "FDA Approved" badge, and FDA's reply is a single sentence with nothing to interpret: compounded drug products are not FDA-approved. That distinction matters when you are deciding how much weight to give any one letter. An inference can be argued about; a direct claim of approval either matches the record or it does not, and this one did not. The practical consequence is narrow and specific. "FDA-approved" next to a monthly price is the single strongest reason a shopper has to stop comparing and buy, because it appears to end the question of whether the product works. It did not end that question here, and the letter says so without saying anything at all about whether the medication is safe or what it should cost.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Maxlife failed to respond.